Skip to main content

Table 1 Patient characteristics

From: Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Parameter 50 mg/m2 (N = 4) 100 mg/m2 (N = 5) 200 mg/m2 (N = 3) 300 mg/m2 (N = 3) 400 mg/m2 (N = 3) 500 mg/m2 (N = 7) 600 mg/m2 (N = 1) Total (N = 26) %
Gender
 Male 3 3 2 1 3 6 0 18 69
 Female 1 2 1 2 0 1 1 8 31
Race
 Caucasian 3 4 3 3 2 6 1 23 89
 Black 0 1 0 0 1 1 0 3 11
Age (years, at screening)
 Mean (SD) 64.645 (11.7737) 60.716 (13.5373) 62.387 (20.6538) 68.227 (15.4956) 74.25 (11.0807) 67.104 (9.5240) 65.92 (NA) 65.9 (12.14)  
 Median 66.92 59.43 61.370 70.500 69.00 66.98 65.92 66.9  
 Range 49.84–74.9 41.0–77.3 42.26–83.53 51.72–82.76 66.77–86.98 53.65–79.69 65.92 41–87  
Type of malignancy
 CLL 4 4 4 3 3 5 0 23 89
 Multiple Myeloma 0 0 0 0 0 2 1 3 11
Time from diagnosis to first samalizumab dose (days)
 Mean (SD) 3672.3 (3323.28) 1556.6 (1571.86) 3017.0 (912.22) 1577.3 (1010.13) 3371.0 (2045.69) 1850.4 (1190.99) 1451.0 (NA) 233 (1817.1)  
 Median 2510.5 813.0 2922.0 1264.0 3061.0 1649.0 1451.0 1887  
 Range 1148–8520 43–4200 2156–3973 761–2707 1498–5554 154–3123 1451–1451 154–8520  
 Patients with previous chemotherapy 3 3 3 3 2 7 1 22 85
 Patients with previous radiation 0 0 0 0 0 1 1 2 8
 Patients without prior chemotherapy or radiation treatments 1 2 0 0 1 0 0 4 15
Study completion
 Yes 2 3 0 1 1 2 0 9 34.6
 No 2 2 3 2 2 5 1 17 65.4
Reason for non-completion
 Treatment-emergent adverse event 1 0 1 2 1 0 0 5 19.2
 Patient requested to withdraw 1 0 1 0 0 2 0 4 15.4
 Lack of efficacy 0 0 0 0 1 2 0 3 11.5
 Investigator considered it advisable/in the patient’s best interest 0 0 0 0 0 1 1 2 7.7
 Patient did not complete follow up 0 1 0 0 0 0 0 1 3.8
 Death (not related to study drug) 0 1 0 0 0 0 0 1 3.8
 Positive antidrug antibody serology 0 0 1 0 0 0 0 1 3.8